Partner David Rosen is quoted in a Pink Sheet article, “Gottlieb’s Complex Generics Remarks Could Signal (Some) Increased Flexibility,” about FDA Commissioner Scott Gottlieb’s remarks on generic copies of products with drug and device constituent parts at an internal FDA event for agency scientists and researchers, where he reinforced the agency’s position to permit a generic product to have certain labeling differences from the branded product if the changes are a result of a permitted design difference.
Rosen said Gottlieb’s remarks appear to signal “a little more flexibility” if changes such as those to a delivery device do not raise clinical efficacy or safety issues. That could include a change from “an open-up, actuate, and click-to-actuate” delivery system to a system that has a “lever that you push or pull,” he said.
“I think that it will really be evaluated on a case-by-case basis to make sure that whatever modifications in or changes in the labeling and in these drug-device combination situations don’t raise safety or clinical efficacy types of issues,” he added.
Rosen said Gottlieb’s remarks appear to signal “a little more flexibility” if changes such as those to a delivery device do not raise clinical efficacy or safety issues. That could include a change from “an open-up, actuate, and click-to-actuate” delivery system to a system that has a “lever that you push or pull,” he said.
“I think that it will really be evaluated on a case-by-case basis to make sure that whatever modifications in or changes in the labeling and in these drug-device combination situations don’t raise safety or clinical efficacy types of issues,” he added.
People
Related News
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."
August 1, 2025
In the News
Aaron Maguregui Assesses HIPAA Challenges as AI Advances in Health Care
Foley & Lardner LLP partner Aaron Maguregui commented in the Medical Device Network article, "AI proliferation in healthcare shines light on HIPAA shortcomings," assessing the rise and accompanying risks of artificial intelligence in health care.